Nasdaq

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...
Monthly Prescribing Reference

Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
KOIN 6

LifeNet Health LifeSciences launches TruVivo™, a pioneering all-human 2D+ hepatic system, to revolutionize compound discovery

TruVivo, the largest co-culture advancement in more than a decade, is a novel hepatic in vitro 2D+ system comprised of all-human cells that mimics the microarchitecture and functionality of the human ...
pix11

Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Results show that percutaneous hepatic perfusion with CHEMOSAT ® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in ...
Pharmabiz

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma

Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...